EUVIMEDEUVIMED entdecken
Crossref

Engineered Stem Cell Booster Breaks Pathological Barriers to Treat Chronic Pancreatitis

Han Han, Bi-Te Chen, Yang Liu, Liang Qi, Lei Xing, Hui Wang, Min Zhao, Chen Zhang, Ping Yu, Ning Wei, Jing Wang, Fang Zhou und 5 weitere

Advanced Materials · 2025-04 · 37 (14)

DOI: 10.1002/adma.202416261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 27.02.2025. Verfasst von Han Han und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, 210009, P. R. China. Hauptthemen laut MEDLINE: Pancreatitis, Chronic, Mesenchymal Stem Cells, Mesenchymal Stem Cell Transplantation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Basic Research Program-Project jointly.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic pancreatitis (CP) is a long‐standing progressive fibrosis and has long been considered incurable, which remains a heavy health burden worldwide. Mesenchymal stem cells (MSCs) with anti‐fibrosis properties are currently used in the treatment of fibroinflammatory diseases. However, its therapeutic effect is limited mainly due to two main types of pathological barriers in CP: 1) Fibrotic collagen hinders cell delivery, and 2) Malignant microenvironment attacks cell inactivation. Here, a MSCs‐based exogenous nitric oxide (NO) delivery system (MSCs‐Lip@RNO) is constructed. In the MSCs‐Lip@RNO, NO not only can be a cell booster to regulate collagen fibers, relieve the vascular compression and enhance the accumulation of MSCs in the whole pancreas, but also can form a protective gas layer on the cell surface, which enhances the therapeutic effect of MSCs. In the CP rat model, the pancreatic injury and fibrosis are reduced with 7 days after a single dose administration of this long‐acting MSCs. Collectively, this study offers a promising strategy for enhancing the delivery and therapeutic efficacy of MSCs to break pathological barriers in CP treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatitis, ChronicMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsRatsNitric OxideMaleFibrosisRats, Sprague-DawleyPancreasHumansCollagen

Stichwörter der Autor:innen

chronic pancreatitisengineered stem cellnitric oxidepancreatic fibrosispathological barriers

Substanzen

Nitric OxideCollagen

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, 210009, P. R. China.
  • Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, P. R. China.
  • College of Pharmacy, Yanbian University, Yanji, 133002, P. R. China.
  • State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing, 210009, P. R. China.
  • School of Engineering, China Pharmaceutical University, Nanjing, 210009, P. R. China.
  • Jiangsu Renocell Biotech Co., Ltd, Nanjing, 211100, P. R. China.

ORCID-Profile: Hu-Lin Jiang

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Basic Research Program-Project jointly
  • Jilin Provincial Foundation of Changbai Talent Outstanding Team
  • Priority Academic Program Development of Jiangsu Higher Education Institutions
  • "111" Project from the Ministry of Education of China
  • State Administration of Foreign Experts Affairs of China
  • National Key Research and Development Program of China

Zitieren

APA

Han, H., Chen, B. T., Liu, Y., Qi, L., Xing, L., Wang, H., Zhao, M., Zhang, C., Yu, P., Wei, N., Wang, J., Zhou, F., Wang, G. J., Cheng, X. W., Huang, Z. J., Li, L., & Jiang, H. L. (2025). Engineered Stem Cell Booster Breaks Pathological Barriers to Treat Chronic Pancreatitis. Advanced Materials, 37(14). https://doi.org/10.1002/adma.202416261

Vancouver

Han H, Chen BT, Liu Y, Qi L, Xing L, Wang H, et al. Engineered Stem Cell Booster Breaks Pathological Barriers to Treat Chronic Pancreatitis. Advanced Materials. 2025;37(14). doi:10.1002/adma.202416261

BibTeX
@article{Han2025,
  author = {Han, Han and Chen, Bi-Te and Liu, Yang and Qi, Liang and Xing, Lei and Wang, Hui and Zhao, Min and Zhang, Chen and Yu, Ping and Wei, Ning and Wang, Jing and Zhou, Fang and Wang, Guang-Ji and Cheng, Xian-Wu and Huang, Zhang-Jian and Li, Ling and Jiang, Hu-Lin},
  title = {Engineered Stem Cell Booster Breaks Pathological Barriers to Treat Chronic Pancreatitis},
  journal = {Advanced Materials},
  year = {2025},
  volume = {37},
  number = {14},
  doi = {10.1002/adma.202416261}
}
Kostenlos starten →